# Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

> **NCT00815919** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 22 (actual)

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** bortezomib
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00815919
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2012-01
- **Final completion:** 2013-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2015-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00815919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00815919, "Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00815919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*